Human CRISPR Activation Calabrese Library，1KIT，PCRISPR001-1KT，Sigma

General description

The Human CRISPR activation library (Calabrese) activates over 18,000 human genes and is used for genome-wide activation screening. The library is designed to be compact and efficient to maximize screening efficiency and performance, as published by Sanson, K.R., et al. Nat Commun 9, 5416 (2018).

Custom pools for follow-up screening or 10x Genomics Compatible CRISPR pools are also available by contacting your local sales representative.

Application

• Functional Genomics/Target Validation
• Focused forward genetic activation screening
• Validated positive and negative controls

Biochem/physiol Actions

The most effective CRISPRa system uses the CRISPR Synergistic Activation Mediator (SAM) complex. This platform combines VP64-dCas9 with a modified guide. In addition, the gRNA contains two aptamers that recruit additional co-activators, p65 and HSF1, enhancing target gene activation.

CRISPRa can also serve as a complementary approach to loss-of-function (LOF) genetic screens by enriching for a different set of genes responsible for a phenotype CRISPRa screens show little-to-no off-target activity and can be used to study genes that are difficult to characterize using only LOF approaches because of their high copy number.

Features and Benefits

• Focus on your research, and we will generate your lentivirus screening library
• Compatible with SAMHELPERV for consistent effector expression across a wide variety of cell lines dCas9-VP64-Blasticidin MS2-P65-HSF1-Hygromycin
• Targeting Genes 18,885 (Set A), 18,843 (Set B)
• Compact Libary with gRNAs56,762 (Set A), 56,476 (Set B)
• Built-in Controls 500, unique non-targeting controls are in each of the two half-libraries (Set A and Set B)

Other Notes

2 Subpools with a minimum concentration of 5x10⁸ VP/mL(via p24 assay)
PCRISPR001A - Human CRISPR Activation Calabrese Library Set A
PCRISPR001B - Human CRISPR Activation Calabrese Library Set B

Legal Information

CRISPR USE LICENSE AGREEMENT

LENTIVIRAL, WPRE AND EVROGEN FLUOROPHORE LICENSES